Juno Therapeutics Inc (NASDAQ:JUNO) shares traded up 6.3% on Tuesday . The stock traded as high as $31.45 and last traded at $31.17, with a volume of 1,596,736 shares. The stock had previously closed at $29.32.

Several research analysts have recently weighed in on the stock. Vetr lowered shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $53.00 price objective on the stock. in a research note on Monday, June 6th. FBR & Co restated a “buy” rating on shares of Juno Therapeutics in a research note on Monday, June 6th. Zacks Investment Research lowered shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, April 25th. SunTrust Banks Inc. restated a “buy” rating and set a $50.00 price objective on shares of Juno Therapeutics in a research note on Wednesday, April 20th. Finally, Raymond James Financial Inc. assumed coverage on shares of Juno Therapeutics in a research note on Thursday, June 2nd. They set an “outperform” rating and a $52.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $54.19.

The firm’s market capitalization is $3.00 billion. The stock’s 50 day moving average price is $36.57 and its 200-day moving average price is $37.32.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.26. During the same quarter in the prior year, the company posted ($0.30) EPS. The firm earned $9.80 million during the quarter, compared to analysts’ expectations of $4.83 million. On average, analysts expect that Juno Therapeutics Inc will post ($2.28) earnings per share for the current fiscal year.

In other news, Director Richard Klausner sold 12,000 shares of the firm’s stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $40.00, for a total transaction of $480,000.00. Following the transaction, the director now owns 858,799 shares in the company, valued at $34,351,960. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Bernard J. Cassidy sold 3,116 shares of the firm’s stock in a transaction on Thursday, May 19th. The shares were sold at an average price of $39.03, for a total value of $121,617.48. Following the transaction, the general counsel now owns 55,511 shares in the company, valued at approximately $2,166,594.33. The disclosure for this sale can be found here.

A number of large investors recently modified their holdings of the stock. California Public Employees Retirement System increased its stake in shares of Juno Therapeutics by 878.7% in the fourth quarter. California Public Employees Retirement System now owns 105,700 shares of the biopharmaceutical company’s stock worth $4,648,000 after buying an additional 94,900 shares during the last quarter. US Bancorp DE increased its stake in shares of Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock worth $3,900,000 after buying an additional 1,600 shares during the last quarter. Swiss National Bank bought a new stake in shares of Juno Therapeutics during the fourth quarter worth $2,603,000. BNP Paribas Arbitrage SA increased its stake in shares of Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock worth $2,252,000 after buying an additional 10,884 shares during the last quarter. Finally, BBR Partners LLC bought a new stake in shares of Juno Therapeutics during the fourth quarter worth $1,539,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.